Natco Pharma share climbs 7% as firm seeks nod for COVID-19 drug
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication, according to a press release from Natco
BusinessToday.In | April 26, 2021 | Updated 16:17 IST
NATCO is hoping that CDSCO would give emergency approval of this drug based on compassionate use for patients
The share price of Natco Pharma rose over 7 per cent today after the company announced that it has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of COVID-19 positive patients.
Explore Now
NEW DELHI: Domestic benchmark indices continued their consolidation phase as the focus of investors turned to increasing Covid cases and state-wise restrictions, forcing investors to reconsider the current high valuations despite a fall in earnings.
On the global front, a possible hike in capital gains tax in the US also took a toll on global equities. Pharma and metal ended with healthy gains whereas all the other indices traded subdued. Realty, FMCG and auto were the top losers.
However, analysts are hopeful that a bottom will be formed soon. Goldman Sachs Research estimated that assuming a faster ramp-up in Sputnik vaccine production, around 60% of India’s population or 95 per cent of its adult population will be inoculated by year-end. That does not take into account a potential partnership between Pfizer and local manufacturers, or other bilateral import arrangements.
Zydus Cadila s Virafin granted restricted emergency use approval for treating COVID patients: DBT dailyexcelsior.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyexcelsior.com Daily Mail and Mail on Sunday newspapers.
Zydus
In a big boost to the national effort against COVID-19, Ahmedabad-based pharmaceutical major Zydus Cadila on Friday (23 April) announced that the company has received Restricted Emergency Use Approval (EUA) from the Drug Controller General of India (DCGI) for the use of âVirafinâ, Pegylated Interferon alpha-2b (PegIFN,) in treating moderate COVID-19 infection in adults.
The company has claimed that a single dose subcutaneous regimen of the Virafin developed by it can help patients recover faster and avoid complications if the drug is administered to them early on during COVID-19. In the multicentric trial conducted in 20-25 centers across India, Virafin had shown lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating COVID-19, Zydus Cadila said in a statement.
NEW DELHI: Drug Controller General Of India (DCGI) has granted restricted emergency use approval to Zydus Cadila s Virafin for treating patients showing moderate Covid-19 symptoms, the department of biotechnology said on Saturday.
Virafin is a pegylated interferon alpha-2b(PegIFN), which when subcutaneously injected to the patient in the early stages of infection, results in their faster recovery, it said.
The studies confirmed the safety, tolerability and efficacy of Virafin. The studies also reported that Viarfin reduces viral load and aid in managing the disease in a better way, such as reduction in the need for supplemental oxygen, thereby reducing the respiratory tension caused due to low oxygen levels, the DBT said.